Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beilei Wang

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
Investigational New Drugs|December 25, 2019
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsLi Wang, Chen Hu, Aoli Wang, et al.
Haematologica|April 18, 2020
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemiaAoli Wang, Chen Hu, Cheng Chen, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaXiaofei Liang, Beilei Wang, Cheng Chen, et al.
Oncotarget|April 15, 2017
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding modeChen Hu, Aoli Wang, Hong Wu, et al.
Oncotarget|January 18, 2018
Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)Kailin Yu, Xuesong Liu, Zongru Jiang, et al.
Cancer Biology & Therapy|March 22, 2019
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)Jiaxin Wu, Aoli Wang, Xixiang Li, et al.
Journal of Medicinal Chemistry|March 11, 2017
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding ModeAoli Wang, Xixiang Li, Hong Wu, et al.
European Journal of Medicinal Chemistry|September 26, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorBeilei Wang, Jiaxin Wu, Yun Wu, et al.
Scientific Reports|March 30, 2017
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis modelHong Wu, Qiong Huang, Ziping Qi, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
Investigational New Drugs|December 25, 2019
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia modelsLi Wang, Chen Hu, Aoli Wang, et al.
Haematologica|April 18, 2020
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemiaAoli Wang, Chen Hu, Cheng Chen, et al.
Journal of Medicinal Chemistry|December 20, 2018
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid LeukemiaXiaofei Liang, Beilei Wang, Cheng Chen, et al.
Oncotarget|April 15, 2017
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding modeChen Hu, Aoli Wang, Hong Wu, et al.
Oncotarget|January 18, 2018
Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)Kailin Yu, Xuesong Liu, Zongru Jiang, et al.
Cancer Biology & Therapy|March 22, 2019
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)Jiaxin Wu, Aoli Wang, Xixiang Li, et al.
Journal of Medicinal Chemistry|March 11, 2017
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding ModeAoli Wang, Xixiang Li, Hong Wu, et al.
European Journal of Medicinal Chemistry|September 26, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorBeilei Wang, Jiaxin Wu, Yun Wu, et al.
Scientific Reports|March 30, 2017
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis modelHong Wu, Qiong Huang, Ziping Qi, et al.
Pageof 18